Clinical trials: Progesterone Receptor Negative
Advanced Solid Tumors, Metastatic Triple Negative Breast Cancer
Study of NK012 and Carboplatin in Solid Tumors With Dose Expansion in Triple Negative Breast Cancer
The primary objective is to determine the maximum tolerated dose/recommended phase II dose of the combination regimen of NK012 and carboplatin in patients with advanced solid tumors.
- Trial name
- NCT01238952
- Testing
- NK012 and carboplatin
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Nippon Kayaku Co., Ltd.
Pain, Knee Osteoarthritis
A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
The purpose of this study is to evaluate whether tapentadol (CG5503) prolonged-release (PR) tablets at doses of 100-250 mg twice daily provide a better pain relief in patients with moderate to severe chronic pain due to…
- Trial name
- NCT00486811
- Testing
- Tapentadol ER (100 to 250 mg twice daily), Oxycodone CR (20 to 50 mg twice daily)
- Where
- 100 sites in Austria, Croatia and 11 more
- Volunteers
- 990 people
- Sponsor
- Grünenthal GmbH
Breast Neoplasms
An Efficacy Study of Trabectedin in the Treatment of Participants With Specific Subtypes of Metastatic Breast Cancer
The purpose of this study is to evaluate the effectiveness and safety of trabectedin in 3 subpopulations of participants with previously treated progressive metastatic ( spread of a cancer from one organ or part to another…
- Trial name
- NCT00580112
- Testing
- Dexamethasone, Trabectedin
- Where
- 33 sites in United States, France and 2 more
- Volunteers
- 127 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Advanced Breast Cancer
Study to Assess the Safety of Alpelisib Plus Fulvestrant, in Men and Post-menopausal Women With HR-positive, HER2-negative, Advanced Breast Cancer (aBC) With PIK3CA Mutation, Whose Disease Progressed on or After Endocrine Treatment
The purpose of this study was to determine the safety of alpelisib plus fulvestrant in men and post-menopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced or…
- Trial name
- ALPINIST (NCT05631795)
- Testing
- Alpelisib, Fulvestrant
- Where
- 12 sites in India
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Breast Tumor, Breast Cancer
Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in combination with either gemcitabine or carboplatin to the combination of gemcitabine and carboplatin as first line treatment in female subjects…
- Conditions
- Breast Tumor, Breast Cancer, Cancer of the Breast, Estrogen Receptor- Negative Breast Cancer
- Trial name
- tnAcity (NCT01881230)
- Testing
- nab-Paclitaxel, Carboplatin, Gemcitabine
- Where
- 140 sites in United States, Australia and 10 more
- Volunteers
- 191 people
- Sponsor
- Celgene
Breast Cancer, Metastasis
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
- Trial name
- NCT00371345
- Testing
- Dasatinib, Dasatinib 100 mg
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer
A Trial to Evaluate the Combination of Iressa & Faslodex® in Patients With Advanced or Metastatic Breast Cancer
The progression free survival and efficacy of 250 mg ZD1839 in combination with a fixed dose of fulvestrant 250 mg im once a month will be evaluated in female patients with histologically-confirmed advanced or metastatic, ER…
- Trial name
- NCT00234403
- Testing
- gefitinib and fulvestrant
- Where
- 7 sites in Spain
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Advanced, Metastatic Breast Cancer
Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer
The primary purpose of this study was to assess the efficacy of ribociclib, as measured by progression free survival (PFS), in postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor 2…
- Trial name
- MONALEESA-2 (NCT01958021)
- Testing
- Ribociclib, Letrozole
- Where
- 221 sites in United States, Argentina and 27 more
- Volunteers
- 668 people
- Sponsor
- Novartis Pharmaceuticals
Parkinson's Disease With Severe Pain
A Randomised Placebo Controlled Study of OXN PR for Severe Parkinson's Disease Associated Pain
To demonstrate superiority of OXN PR compared to placebo with respect to analgesic efficacy in subjects with chronic severe pain associated with Parkinson's disease (PD), as assessed by averaged 24 hour pain scores collected for…
- Trial name
- NCT01439100
- Testing
- Oxycodone/Naloxone Prolonged Release tablets
- Where
- 31 sites in Czechia, Germany and 5 more
- Volunteers
- 172 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Cancer, Pain
Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer Pain
To Determine the Safety and Efficacy of Oxycodone / Naloxone Prolonged Release Tablets compared to Oxycodone PR in Subjects with Moderate to Severe, Chronic Cancer Pain
- Trial name
- NCT01885182
- Testing
- Oxycodone/Naloxone, Oxycodone
- Where
- 28 sites in China
- Volunteers
- 232 people
- Sponsor
- Mundipharma (China) Pharmaceutical Co. Ltd
Hypoxia
Accuracy of Pulse Oximeters With Profound Hypoxia At Rest (NIHO18)
The aim of this study is to determine the accuracy of devices called pulse oximeters, which measure blood oxygen by shining light through fingers, ears or other skin, without requiring blood sampling.
- Trial name
- NCT05807464
- Testing
- Pulse Oximeter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Nihon Kohden
Prolonged QTc Interval, Pharmacokinetic
Effect of a Multiple-dose Oral Administration of CG5503 PR on the Electrical Activity of the Heart in 48 Healthy Men and Women
The effect of multiple oral administration of two doses of CG5503 PR (prolonged release) compared to placebo on the electrical activity of the heart were investigated.
- Trial name
- NCT03951402
- Testing
- 100 mg CG5503 (tapentadol hydrochloride) PR tablet, 400 mg Moxifloxacin tablet (overencapsulated)
- Where
- Germany
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Grünenthal GmbH
Breast Cancer
A Companion Sample Collection Protocol to Support the Discovery of Breast Cancer Aberrations With Treatment of CDK4/6 Therapy/LEE011/Ribociclib
This study was a companion study to CLEE011A2404 which provided the opportunity for the collection of tumor tissue samples to better understand relevant mutations and the mechanisms responsible for resistance to treatment.
- Trial name
- NCT03050398
- Testing
- Ribociclib, letrozole
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Respiratory System Disease, Chronic Obstructive Pulmonary Disease
The Study for Evaluating the Clinical Effectiveness and Safety of Respiratory Rehabilitation Software 'Redpill Breath'(COPD, Asthma, Lung Cancer, Etc.)
The purpose of the study is to prove the clinical superiority of respiratory rehabilitation software "Redpill Breath" and evaluate the clinical improvement effect by 6-minute walk test of the software, compared to the manual…
- Conditions
- Respiratory System Disease, Chronic Obstructive Pulmonary Disease, Asthma Copd, Lung Cancer
- Trial name
- NCT05299385
- Testing
- Conventional rehabilition treatment(e.g leaflet) educated by hospital, Digital treatment based on Respiratory Rehabilitation Software
- Where
- 3 sites in South Korea
- Volunteers
- 100 people
- Sponsor
- Lifesemantics Corp.
HIV-1
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
The objective of this steady state pivotal study is to compare the rate and extent of absorption and to evaluate Bioequivalence of test drug compared to the approved reference product in HIV infected individuals
- Trial name
- NCT02202005
- Testing
- Nevirapine, Viramune®
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Ratiopharm GmbH
Breast Cancer
An Open-Label, Expanded Access Protocol of Iniparib Breast Cancer
The following trial is designed to offer pre-approval drug access to iniparib in combination with gemcitabine and carboplatin in order to provide potential clinical benefit to patients with ER-, PR-, and HER2-negative metastatic…
- Trial name
- NCT01130259
- Testing
- iniparib
- Sponsor
- Sanofi
Osteoarthritis, Back Pain
A Study to Compare Oxycodone/Naloxone Prolonged Release Against Codeine/Paracetamol in the Treatment of Moderate to Severe Chronic Low Back Pain or Pain Due to Osteoarthritis
The purpose of this study is to compare oxycodone/naloxone combination tablet and codeine/paracetamol tablets in the treatment of moderate to severe chronic low back pain or pain due to osteoarthritis.
- Trial name
- NCT00784810
- Testing
- Oxycodone/Naloxone, Codeine/Paracetamol
- Where
- United Kingdom
- Volunteers
- 247 people
- Sponsor
- Napp Pharmaceuticals Limited
Breast Cancer
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer.
- Trial name
- NCT07062965
- Testing
- PF-07248144, Fulvestrant, Everolimus
- Where
- 433 sites in United States, Argentina and 29 more
- Volunteers
- 400 people
- Sponsor
- Pfizer
Parkinson Disease
Clinical Evaluation of Ropinirole Prolonged Release/Extended Release (PR/XR) Tablet for Adjunctive Therapy to L-dopa in Subjects With Advanced Parkinson's Disease
To investigate the efficacy and the safety of ropinirole PR/XR tablets to ropinirole immediate release (IR) tablets with advanced Parkinson's disease in conjunction with L-dopa in a double-blind, parallel group comparison study.
- Trial name
- NCT00823836
- Testing
- ropinirole PR/XR, ropinirole IR
- Where
- 54 sites in Japan
- Volunteers
- 302 people
- Sponsor
- GlaxoSmithKline
Moderate to Severe Chronic Non-cancer Pain
A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain
The purpose of this study is to evaluate the safety and effectiveness of prolonged release tapentadol hydrochloride for the relief of moderate to severe chronic non-cancer pain among Filipino patients.
- Trial name
- NCT01719588
- Testing
- No intervention
- Sponsor
- Janssen Pharmaceutica